Abstract
Background. Cancer-induced venous pathology, including deep vein thrombosis and pulmonary embolism, is one of the most common and prognostically adverse complications in patients with malignancies. The chronicity of the cancer process brings the assessment of health-related quality of life (HRQoL) to the forefront. However, the impact of venous thromboembolic events (VTE) on the quality of life of cancer patients remains insufficiently studied. Purpose of the study. To systematically review current evidence on the impact of cancer-induced venous pathology on the quality of life of chronic cancer patients, identify the main determinants of this impact, and highlight directions for optimizing the management of this patient population. Methods. A systematic literature review was conducted, including Russian and international publications up to 2025, of which 75% were from the last five years. Search was performed in PubMed, Scopus, Web of Science, eLibrary, and RSCI databases. Results. The incidence of VTE in patients with solid tumors reaches 9.7% and varies depending on tumor site, stage, and therapy. The development of VTE is associated with a clinically significant reduction in all components of quality of life (physical, role, emotional, and social functioning) according to EORTC QLQ-C30, PEmb-QoL, and VEINES-QOL/Sym questionnaires. Qualitative studies have identified a lack of knowledge about VTE among patients and physicians, marked psychological distress (fear of recurrent thrombosis, anxiety, depression), difficulties associated with long-term anticoagulant therapy, and social isolation. Post-thrombotic syndrome develops in 20-50% of patients and is a leading factor in long-term quality of life reduction. Direct oral anticoagulants, compared to low-molecular-weight heparins, have advantages in terms of quality of life but require careful patient selection. A multidisciplinary approach involving an oncologist, hemostasis specialist, nurse, psychologist, and a physiotherapist, and the implementation of integrated care models improve treatment adherence and quality of life. Conclusion. Cancer-induced venous pathology significantly and persistently reduces the quality of life of cancer patients. An optimal management strategy includes early diagnosis, individualized anticoagulant therapy considering patient preferences, active detection and management of post-thrombotic syndrome, psychological support, and educational programs. Further research is needed to develop specific quality-of-life assessment tools for this cohort, conduct comparative anticoagulant trials with quality of life as a primary endpoint, and optimize care delivery models.

This publication has 44 references indexed in Scilit: